ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1631

Osteoarthritis-Associated Basic Calcium Phosphate Crystals Induce IL-1β, IL-18 and S100A8 Production in a Tyrosine Kinase Dependent Manner

Geraldine M. McCarthy1, Evanna Mills2, Kingston Mills2 and Aisling Dunne2, 1Medicine/Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, 2School of Biochemistry and Immunology, Trinity College Dublin, Dublin 2, Ireland

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: OA and crystal-induced arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Metabolic and Crystal Arthropathies: Basic Science

Session Type: Abstract Submissions (ACR)

Background/Purpose: Intraarticular basic calcium phosphate (BCP) crystals are present in the majority of osteoarthritic (OA) joints and are associated with severe degeneration. In vitro, BCP promote pro-inflammatory cytokine production and matrix metalloprotease (MMP) expression, suggesting a pathogenic role in OA. Recently it has been demonstrated that BCP crystals drive IL-1β and IL-18 production following activation of the NOD-like receptor, NLRP3. Here, we sought to determine whether uptake of BCP crystals leads to the activation of the membrane proximal kinases, Syk and PI3 kinase and to further characterise events downstream of Syk activation in order to identify novel molecular targets for the treatment of BCP related arthropathies.

Methods: Murine  macrophages were stimulated with BCP crystals, with or without priming with a Toll-like receptor (TLR) agonist and IL-1β and IL-18 production was quantified by enzyme linked immunosorbent assay (ELISA). A role for Syk and PI3 kinase was determined with the use of the inhibitors, piceatannol and LY294002, respectively. Activation of the kinases was confirmed by western blotting using phospho-specific antibodies to Syk and PI3 kinase following treatment of cells with the crystals over a 30 minute time course. Finally, activation of the downstream kinase, ERK, and production of the damage associated molecule, S100A8, was assessed in the presence of piceatannol in order to determine if these events are associated with BCP dependent Syk activation.  

Results:

Physiological concentrations of BCP crystals (50mg/ml) induced robust IL-1β and IL-18 production in a Syk and PI3 kinase dependent manner. Treatment with the inhibitors piceatannol and Ly294002 led to a significant reduction in cytokine levels (>80%) and activation of Syk and PI3 kinase was apparent after approximately 5 minutes treatment with the crystals. Phosphorylation of the downstream kinase, ERK, was prevented following treatment with the Syk inhibitor, piceatannol, thus identifying Syk kinase activation as a proximal event in BCP induced pro-inflammatory cytokine production. Finally, treatment of cells with BCP crystals led directly to the production of the danger-associated molecule, S100A8 and this was also dependent on activation of Syk.

Conclusion: Since S100A8 is considered a TLR 4 ligand, we propose a model whereby BCP crystals drive the production of S100A8 which in turn leads to the expression of pro-IL-1β and pro-IL-18 (Signal 1). In macrophages, BCP crystals can also induce the activation of the NLRP3 inflammasome (Signal 2) leading to the production of the mature forms of these cytokines. These events are dependent on tyrosine phosphorylation and we identify Syk kinase as a potential target for the treatment of BCP related pathologies


Disclosure:

G. M. McCarthy,
None;

E. Mills,
None;

K. Mills,
None;

A. Dunne,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/osteoarthritis-associated-basic-calcium-phosphate-crystals-induce-il-1%ce%b2-il-18-and-s100a8-production-in-a-tyrosine-kinase-dependent-manner/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology